|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Retrograde-viewing device improves adenoma detection rate in colonoscopies for surveillance and diagnostic workup显示文摘AIM:To determine which patients might benefit most from retrograde viewing during colonoscopy through subset analysis of randomized,controlled trial data.METHODS:The Third Eye Retroscope Randomized Clinical Evaluation(TERRACE) was a randomized,controlled,multicenter trial designed to evaluate the efficacy of a retrograde-viewing auxiliary imaging device that is used during colonoscopy to provide a second video image which allows viewing of areas on the proximal aspect of haustral folds and flexures that are difficult to see with the colonoscope's forward view.We performed a post-hoc analysis of the TERRACE data to determine whether certain subsets of the patient population would gain more benefit than others from use of the device.Subjects were patients scheduled for colonoscopy for screening,surveillance or diagnostic workup,and each underwent same-day tandem examinations with standard colonoscopy(SC) and Third Eye colonoscopy(TEC),randomized to SC followed by TEC or vice versa.RESULTS:Indication for colonoscopy was screening in 176/345 subjects(51.0%),surveillance after previous polypectomy in 87(25.2%) and diagnostic workup in 82(23.8%).In 4 subjects no indication was specified.Previously reported overall results had shown a net additional adenoma detection rate(ADR) with TEC of 23.2% compared to SC.Relative risk(RR) of missing adenomas with SC vs TEC as the initial procedure was 1.92(P = 0.029).Post-hoc subset analysis shows additional ADRs for TEC compared to SC were 4.4% for screening,35.7% for surveillance,55.4% for diagnostic and 40.7% for surveillance and diagnostic combined.The RR of missing adenomas with SC vs TEC was 1.11(P = 0.815) for screening,3.15(P = 0.014) for surveillance,8.64(P = 0.039) for diagnostic and 3.34(P = 0.003) for surveillance and diagnostic combined.Although a multivariate Poisson regression suggested gender as a possibly significant factor,subset analysis showed that the difference between genders was not statistically significant.Age,bowel prep quality and withdrawal time did not significantly affect the RR of missing adenomas with SC vs TEC.Mean sizes of adenomas detected with TEC and SC were similar at 0.59 cm and 0.56 cm,respectively(P = NS).CONCLUSION:TEC allows detection of significantly more adenomas compared to SC in patients undergoing surveillance or diagnostic workup,but not in screening patients(ClinicalTrials.gov Identifier:NCT01044732). | Peter D Siersema Amit Rastogi Anke M Leufkens Paul A Akerman Kassem Azzouzi Richard I Rothstein Frank P Vleggaar Alessandro Repici Giacomo Rando Patrick I Okolo Olivier Dewit Ana Ignjatovic Elizabeth Odstrcil James East Pierre H Deprez Brian P Saunders Anthony N Kalloo Bradley Creel Vikas Singh Anne Marie Lennon Daniel C DeMarco | 2012 | World Journal of Gastroenterology2012，18，26： | 6 |
| 2 | Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer 显示文摘 | Safran H Gaissert H Akerman P | 2001 | Cancer Invest2001，19，1： | 1 |
| 3 | Cetuximab,paclitaxel,carboplatin and radiation for esophageal and gastric cancer显示文摘 | Suntharalingam M Dipertrillo T Akerman P | 2006 | J Clin Oncol2006，24，18： | 1 |
| 4 | Flow cytometreic S-phase fraction in soft tissue Sarcoma:prognostic importance analysed in 160 patients显示文摘 | Ferno M Akerman M | 1997 | Br J Cancer1997，75，1： | 1 |
| 5 | Nanocrystal targeting in vivo显示文摘 | Akerman M E Chan W C W Laakkonen P | 2002 | Proceedings of the Na- tional Academy of Sciences of the United States of Amer- ica2002，99，12： | 1 |
| 6 | Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroes ophageal junction 显示文摘 | Safran H Akerman P Cioffi W | 1999 | Semin Radiat Oncol1999，9，1： | 1 |
| 7 | Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas,stomach,and gastroesophageal junction显示文摘 | Safran H Akerman P Cioffi W | 1999 | Semin Radiar Oncol1999，9，1： | 1 |
| 8 | Nanocrystal targeting in vivo显示文摘 | AKERMAN M E CHAN W C LAAKKONEN P | 2002 | Proic Natl Acad Sci USA2002，99，12： | 1 |
| 9 | Nanocrystal Targeting in Vivo显示文摘 | AKERMAN M E CHAN W LAAKKONEN P | 2002 | Proc Natl Acad Sci USA2002，99，12： | 1 |
| 10 | Combined morphologic and karyotypic study of 59 atypical lipomatous tumors(evaluation of their relationship and differential diagnosis with other adipose tissue tumors:a report of the CHAMP study group)显示文摘 | Rosai J Akerman M Dal Cin P | 1996 | Am J Surg Pathol1996，20，10： | 1 |
| 11 | Nanocrystal targeting in vivo显示文摘 | Akerman M E Chan W C Laakkonen P | 2002 | Science2002，99，12： | 1 |
| 12 | Flow cytometreic S-phase fraction in soft tissue Sarcoma:prognostic importance analysed in 160 patients显示文摘 | Gustafson P Ferno M Akerman M | 1997 | Br J Cancer1997，75，1： | 1 |
| 13 | Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepateetomy显示文摘 | Akerman P Cote P Yang SQ | 1992 | Am J Physiol1992，263，41： | 1 |
| 14 | Flow cytomettic S-phase fraction in soft tissue sarcoma: prognostic importance analysed in 160 patients显示文摘 | Gustafson P Ferno M Akerman M | 1997 | Br J Cancer1997，75，1： | 1 |
| 15 | Nanocrystal targeting in vivo显示文摘 | Akerman ME Chan WC Laakkonen P | 2002 | Proc Natl Acad Sci USA2002，99，12： | 1 |
| 16 | Nanocrystal targeting in vivo显示文摘 | M E Akerman W C Chan P Laakkonen | 2002 | Proceedings of the National Academy of Sciences2002，99，12： | 1 |
| 17 | Nanocrystal targeting in vivo显示文摘 | Akerman ME Chan WC Laakkonen P | 2002 | Proc Natl Acad Sci USA2002，99，12： | 1 |
| 18 | Phase I/lI study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma显示文摘 | Safran H Dipetrillo T Akerman P | 2007 | Int J Radiat Oncol Biol Phys2007，67，2： | 1 |
| 19 | Paclitaxel,cisplatin,and concurrent radiation for esophageal cancer显示文摘 | Safran H Gaissert H Akerman P | 2001 | Cancer Invest2001，19，1： | 1 |
| 20 | Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication 显示文摘 | Treacy E P Akerman B R Chow L M | 1998 | Hum Mol Genet1998，7，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员